Background. Despite evidence for beneficial effects of Qishen Yiqi Drop Pill (QSYQ) on congestive heart failure, the majority of studies are based on insufficient sample sizes. The aim of this study was to evaluate the therapeutic effects of QSYQ using a meta-analysis approach. Methodology/Principal Findings. All relevant studies published before December 31, 2019, were identified by searches of various databases with key search terms. In total, 85 studies involving 8,579 participants were included. The addition of QSYQ to routine Western medicine increased 6-minute walking distance (, 95% CI: 1.72–2.44, ), left ventricular ejection fraction (, 95% CI: 0.87–1.23, ), and cardiac index (, 95% CI: 0.92–1.95, ) and reduced brain natriuretic peptide (, 95% CI: -2.81 to -1.76, ), N-terminal prohormone of brain natriuretic peptide (, 95% CI: -3.24 to -1.73, ), left ventricular end-diastolic dimensions (, 95% CI: -1.25 to -0.59, ), and left ventricular end-systolic dimensions (, 95% CI: -0.89 to -0.21, ). The results were stable in subgroup analyses and sensitivity analyses. Conclusions. Our current meta-analysis indicated that QSYQ combined with Western therapy might be effective in CHF patients. Further researches are needed to identify which subgroups of CHF patients will benefit most and what kind of combination medicines work best.

中文翻译：

---

芪参益气滴丸治疗慢性心力衰竭的疗效：85 项研究的最新荟萃分析

背景。尽管有证据表明芪参益气滴丸 (QSYQ) 对充血性心力衰竭有益，但大多数研究都是基于样本量不足。本研究的目的是使用荟萃分析方法评估 QSYQ 的治疗效果。方法论/主要发现。2019 年 12 月 31 日之前发表的所有相关研究都是通过使用关键搜索词搜索各种数据库来确定的。总共纳入了 85 项研究，涉及 8,579 名参与者。常规西药加用 QSYQ 增加了 6 分钟步行距离（, 95% CI: 1.72–2.44,),左心室射血分数 (, 95% CI: 0.87–1.23,)和心脏指数 (, 95% CI: 0.92–1.95,)和减少的脑利钠肽 (, 95% CI: -2.81 至 -1.76,),脑利钠肽 N 端激素原 (, 95% CI: -3.24 至 -1.73,），左心室舒张末期尺寸（, 95% CI: -1.25 至 -0.59,）和左心室收缩末期尺寸（, 95% CI: -0.89 至 -0.21,）。结果在亚组分析和敏感性分析中是稳定的。结论。我们目前的荟萃分析表明，QSYQ 联合西方疗法可能对 CHF 患者有效。需要进一步的研究来确定哪些 CHF 患者亚组将受益最多，以及哪种联合药物效果最好。